Policy developments in the USA and UN paint a positive picture for the potential future international expansion of the company’s medicinal cannabis operations.
() (FRA:9TH) is well-positioned to be a globally significant exporter of TGA and EU GMP medicinal cannabis medicines with the capacity to process large volumes of cannabis with this strategy boosted by recent positive policy changes within the US and at the United Nations.
As owners and operators of one of the world’s largest medicinal cannabis extraction facilities by potential volume, the company welcomes a shift towards more positive attitudes to medicinal cannabis globally.
UN adoption of WHO recommendations
Last week the UN decided to remove cannabis and its derivatives from schedule IV of the 1961 Single Convention on Narcotic Drugs following recommendations from the World Health Organisation (WHO).
This emanated from WHO recommendation 5.1, which recognises the medical value of cannabis and will see it removed from Schedule IV of the 1961 Convention – reserved for substances with ‘particularly dangerous properties’ and little or no therapeutic value.
UN adoption of the WHO recommendations acknowledges the medicinal usefulness of cannabis and clarifies that cannabidiol (CBD) is not under international control.
Positive US policies
The company is also encouraged by positive policy and…
